Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Orellana, Renan ^a,g   Kato, Sumie ^a,g   Erices, Rafaela ^a,g   Bravo, María Loreto ^a,g   Gonzalez, Pamela ^a,g   Oliva, Bárbara ^a,g   Cubillos, Sofía ^a   Valdivia, Andrés ^a   Ibañez, Carolina ^b,c   Brañes, Jorge ^a   Barriga, María Isabel ^d   Bravo, Erasmo ^e   Alonso, Catalina ^e   Bustamente, Eva ^f   Castellon, Enrique ^b   Hidalgo, Patricia ^b   Trigo, Cesar ^b   Panes, Olga ^b   Pereira, Jaime ^b   Mezzano, Diego ^b,c   Cuello, Mauricio A ^a,c,g   Owen, Gareth I ^a,c,g   more..

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c Center UC Investigation in Oncology   (Chile)

^d HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^e Hospital Dr Gustavo Fricke   (Chile)

^f Centro Oncológico Fundación Arturo López Pérez   (Chile)

^g Biomedical Research Consortium of Chile   (Chile)

Author keywords

Ascites; CD44; Coagulation; E Cadherin; EMT; Metastasis initiating cells; N Cadherin

Indexed keywords

BIOLOGICAL MARKER; CHEMOTACTIC FACTOR; THROMBIN RECEPTOR; THROMBOPLASTIN;

BLOOD; CANCER STAGING; CELL COMMUNICATION; CELL MOTION; CLINICAL TRIAL; FEMALE; GENETICS; HUMAN; METABOLISM; MULTICENTER STUDY; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; THROMBOCYTE; TUMOR CELL CULTURE;

BIOMARKERS; BLOOD PLATELETS; CELL COMMUNICATION; CELL MOVEMENT; CHEMOTACTIC FACTORS; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; THROMBOPLASTIN; TUMOR CELLS, CULTURED;

EID: 84928531229     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1304-z     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
4. Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012;322:1-7.
5. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011;6:e16186.
6. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158-66.
7. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-90.
8. Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers. 2011;3:716-29.
9. Imamichi Y, Menke A. Signaling pathways involved in collagen-induced disruption of the E-cadherin complex during epithelial-mesenchymal transition. Cells Tissues Organs. 2007;185:180-90.
10. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76-83.
11. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2:84-9.
12. Vesuna F, van Diest P, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367:235-41.
13. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311-20.
14. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res. 2013;131 Suppl 1:S59-62.
15. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27:4839-47.
16. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821-6.
17. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610-8.
18. Davis AN, Afshar-Kharghan V, Sood AK. Platelet effects on ovarian cancer. Semin Oncol. 2014;41:378-84.
19. Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet. 2009;279:53-6.
20. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576-90.
21. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123-34.
22. Furie B, Furie BC. The molecular basis of blood coagulation. Cell. 1988;53:505-18.
23. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35:103-10.
24. Ruf W. Tissue factor and cancer. Thromb Res. 2012;130 Suppl 1:S84-7.
25. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, et al. Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab. 2005;90:1181-8.
26. Mackman N. The many faces of tissue factor. J Thromb Haemost. 2009;7 Suppl 1:136-9.
27. Carolina Ibanez C, Marcelo Garrido S, Medina L, Kato S, Bravo ML, Gonzalez P, et al. In vitro cell response to chemotherapeutic agents, to personalize ovarian cancer treatment: report of two cases. Rev Med Chil. 2013;141:669-73.
28. Vilos C, Morales FA, Solar PA, Herrera NS, Gonzalez-Nilo FD, Aguayo DA, et al. Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells. Biomaterials. 2013;34:4098-108.
29. Erices R, Bravo ML, Gonzalez P, Oliva B, Racordon D, Garrido M, et al. Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci. 2013;20:1433-46.
30. Pastrana E, Silva-Vargas V, Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011;8:486-98.
31. Panes O, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood. 2007;109:5242-50.
32. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer discovery. 2012;2:1091-9.
33. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res. 2000;6:166-71.
34. Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2013;229:1005-15.
35. Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011;6:e26125.
36. Ladeda V, Aguirre Ghiso JA, Bal de Kier Joffe E. Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells. Exp Cell Res. 1998;242:515-27.
37. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost. 2006;32:24-32.
38. Uchino M, Kojima H, Wada K, Imada M, Onoda F, Satofuka H, et al. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer. 2010;10:414.
39. Sigurdsson V, Hilmarsdottir B, Sigmundsdottir H, Fridriksdottir AJ, Ringner M, Villadsen R, et al. Endothelial induced EMT in breast epithelial cells with stem cell properties. PLoS One. 2011;6:e23833.
40. Masui T, Ota I, Yook JI, Mikami S, Yane K, Yamanaka T, et al. Snail-induced epithelial-mesenchymal transition promotes cancer stem cell-like phenotype in head and neck cancer cells. Int J Oncol. 2014;44:693-9.
41. Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas. 2004;29:132-40.
42. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012;120:4869-72.
43. Kinnman N, Hultcrantz R, Barbu V, Rey C, Wendum D, Poupon R, et al. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest. 2000;80:697-707.
44. Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, Haines KA, et al. Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci U S A. 1991;88:6805-9.
45. Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hamostaseologie. 2014;34:54-62.
46. Placke T, Kopp HG, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 2011;3:374-82.
47. Han LY, Landen Jr CN, Kamat AA, Lopez A, Bender DP, Mueller P, et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol. 2006;24:755-61.
48. Fischer EG, Riewald M, Huang HY, Miyagi Y, Kubota Y, Mueller BM, et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest. 1999;104:1213-21.